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Abstract. A work recently published experimentally demonstrates an increase in the radiobiological efficacy of 
clinical proton beams when a tumour is treated in the presence of a concentration of 11B. The paper, for the first time, 
demonstrates the potential role of the p+11B —> 3α (for brevity, p-B) reaction in the biological enhancement of proton 
therapy effectiveness. The work reports robust experimental data in terms of clonogenic cell survival and 
chromosomal aberrations and unambiguously shows the presence of an enhancement when cells were exposed to a 
clinical proton beam subject to treatment with sodium boroncaptate (BSH). Moreover, the greater occurrence of 
complex-type chromosomal exchanges points to the effect as due radiation of a LET (Linear Energy Transfer) greater 
than that of protons alone, possibly the alpha particles generated by the reaction. At the same time, we emphasized 
that analytical calculations, performed on the basis of the well-known total production cross section data, are not able 
to explain the effect in a macroscopic way, i.e. solely in terms of a trivial increase in the total dose released in the cells 
by the alpha-particles. In this paper, thanks to simulations and analytical calculations, we will discuss the 
theoretically expected alpha particle yield and the corresponding LET and RBE (Relative Biological Effectiveness) 
increase related to the 11B presence. We conclude that a mere calculation based on the classical concepts of integral 
Dose, and average LET and RBE cannot be used to justify the observed radiobiological phenomena. We therefore 
suggest that  micro- and nano-dosimetric aspects must be taken into account. 
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1. INTRODUCTION 
Protontherapy represents one of the fastest 
growing radiotherapy modalities and one of the most 
attractive solutions when radiotherapy is needed, even 
compared to newer and advanced photon-based 
techniques such as intensity modulated radiation 
therapy (IMRT). 
Protons are considered a low-LET (Linear Energy 
Transfer) radiation, with a clinical Relative Biological 
Effectiveness (RBE), assumed to be 1.1 (only ten per-
cent bigger than gamma or x-ray radiation). Such a low 
biological efficiency is considered a limit especially in 
all those cases where radioresistant tumors must be 
treated, for which higher Z ions are preferred (i.e 12C 
ions). For these reasons, the protontherapy community 
is actively investigating the possibility to increase the 
proton biological efficiency by the concomitant use of 
different drugs and/or other agents to radiosensitize 
the tumor. 
In this paper, the possibility to take advantage of 
11B isotope as an agent able to deliver secondary 
particles enhancing the radiobiological effectiveness of 
protons triggering nuclear reactions, is discussed. 
The clinical proton-Boron (p-B) approach was first 
proposed by Do-Kun et al. [1]. They suggested to 
exploit the features of the p(11B,α)2α fusion reaction, 
where low-energy (about 4 MeV) alpha particles are 
generated with a not negligible production cross 
section (around 1.7 barn) for low-energy (resonance at 
about 650 keV) incident protons. 
The Korean group also discussed the possibility to 
use a 719 keV prompt-gamma, emitted in the 
interaction of proton with 11B as an imaging source and 
potential indicator of 11B uptake region. Giuffrida et al. 
[2] and Petringa et al. [3], on the opposite, underlined 
that the gamma emission is not generated from the 
fusion process but from the elastic p(10B, 10B’)p’  
reaction (when using a mixture of 10B and 11B) and 
from the p(11B, 11B’)p’ channel and that, in the latter 
case, at the clinical attainable 11B concentration in 
tissues (order of 10-5 g/cm3), the peak signal would be 
completely masked by the non-prompt components 
generated as protons interact with human body natural 
components (16O mainly). 
The first experimental proof of radiobiological 
enhancement obtained by using the p-B reaction has 
been published by Cirrone et al. [4] irradiating prostate 
cancer cells (DU145) and non-tumorigenic breast 
epithelial MCF-10A cell lines along a 62 MeV clinical 
proton spread out Bragg peak (SOBP) at the Italian 
ocular protontherapy facility of INFN-LNS, Catania, 
Italy. Both clonogenic dose-response curves and 
complex type chromosomal aberration analyses clearly 
showed that the presence of Boron nuclei results in an  
increase of the radiobiological effectiveness of the 
proton beam. Besides the advantage of using a 
neutron-free nuclear fusion reaction, the relevance of 
this method stems from the fact that the reaction 
cross-section becomes significantly high at relatively 
low incident proton energy, i.e. around the Bragg peak 
region. In conventional protontherapy, the beam is 
typically slowed down inside the tumor (the Bragg 
peak region). Thus, most of the beam energy (related 
to the total released dose) is delivered to the tumor 
cells. Assuming that a given concentration of 11B nuclei 
is present preferentially, but not exclusively, in the 
tumor volume, the incoming slow protons can trigger 
fusion reaction events and generate highly DNA-
damaging alpha particles. 
The observed radiobiological enhancement 
reported in [4], even if confirmed in four experimental 
sessions, cannot be still explained making simple use 
of the reaction cross sections knowledge and/or of 
analytical considerations based on the classical 
concepts of dose, LET and RBE. 
In this paper, the calculation of alpha particles 
along the proton SOBP in the irradiation conditions 
used in [4], will be presented in detail and discussed. 
The recent radiobiological experimental results on 
PBCT are briefly recalled in Section 2 while the 
estimation of the generated alpha particles along the 
SOBP and how these affect the LET distributions are 
reported in Section 3 and Section 4. 
2. THE RADIOBIOLOGICAL EVIDENCE 
In order to verify the potentiality of the 11B(p, α)2α  
reaction for the enhancement of cell killing in a 
therapeutic protontherapy scenario, cells from the 
human prostate cancer line DU145 cell line have been 
irradiated at graded doses (0.5, 1, 2, 4 Gy) in the 
middle of a 62-MeV clinical SOBP. 
A significant effect due to the Boron treatment 
(dissolved in the medium 6-8 hr prior to exposure as to 
give a concentration of 80 ppm) was observed 
throughout four experimental campaigns [4]. Based 
upon the measured clonogenic survival dose-
responses, a Dose Modification Factor (or DMF) of 
1.46 ± 0.12 was determined at the 10% survival level. 
This has suggested that the Boron atoms could confer a 
radiobiological advantage in cell killing 
Investigation of structural DNA damages in the 
form of chromosome aberrations (CAs), a well-
acknowledged biomarker of high-LET radiation 
exposure, subsequently confirmed the presence of 
high-LET radiation strongly advocating their  
contribution to the clonogenic results. 
3. IMAGING POTENTIALITIES OF P-11B REACTION 
The presence of Boron within or in the vicinity of 
the neoplastic cells could also be exploited to spatially 
map the biological distribution of Boron nuclei and, 
hence, the tumor regions where the RBE enhancement 
occurs [1]. In particular, the gamma emitted in the 
proton elastic scattering with an 11B nucleus, generates 
a 718 keV  prompt-gamma. The possibility to detect 
such gamma emission could allow 11B localization and, 
consequently, identification of the proton beam 
interaction site. 
Simulations and experimental results conducted by 
Petringa et al. [3] demonstrated that, if a realistic 11B 
concentration is assumed, such prompt-gamma 
emission is impossible to be detected, being completely 
covered by the background gamma rays produced by 
   
proton interaction with other constituents of the 
human body. 
In order to maintain proton-Boron therapeutic 
efficiency and, simultaneously, its imaging capability, 
the use of Boron coupled with natural Copper was 
proposed [5]. Copper can be easily bound to the 
dipyrromethene, BodiPy, a carrier molecule used for 
biological labelling, drug delivery and imaging. Natural 
Copper consists of two stable isotopes (63Cu and 65Cu) 
that can emit several gamma prompt peaks in the 
energy range between 0 to 2 MeV, mostly generated in 
the 63Cu(p,p')63Cu elastic reactions. A combination of 
different prompt-gamma rays could be useful for a 
mapping of the dose. Specifically, the 1.3 MeV gamma 
line could be used, being energetically located very far 
from the spectral region where emission of gamma 
from biological components is present. 
4. MONTE CARLO SIMULATIONS AND ANALYTICAL 
EVALUATIONS TO ESTIMATE THE ALPHA YIELD 
 Monte Carlo (MC) simulations coupled to 
analytical calculations were adopted to estimate the 
total alpha particles produced at the cell site of the 
experiment reported in Cirrone et al. [4] in the attempt 
to explain the observed radiobiological enhancement. 
The proton spectra at various depths in water have 
been reproduced using MC; these, coupled with the 
alpha total production cross section, allowed  to derive 
analytically the expected alpha particle yield. The total 
production cross section was derived from 
experimental data (using the EXFOR [6] database) and 
TALYS [7] calculation, when experimental data were 
not available. 
4.1. Monte Carlo simulations 
Simulations were carried out using the Geant4 
(GEometry ANd Tracking) toolkit [8], version 
10.04.p02 and the official Geant4 advanced example 
Hadrontherapy [9]. This example is able to simulate 
each element of the CATANA (Centro di Adroterapia 
ed Applicazioni Nucleari Avanzate) passive proton 
beam line of the INFN-LNS, where the experimental 
campaigns reported in [4] were performed. 
The simulated geometry includes all the transport 
elements comprising the specific energy modulator to 
generate the SOBP, diagnostic elements and the water 
T-25 flask where cells were positioned. The latter is 
simulated through a box, 40x40x40 mm in dimension, 
divided into slices of water, 100 µm in thickness. Slices 
are perpendicular to the beam axis direction. The 
number of alpha particles was computed in the slices 
along the whole SOBP. 
All the necessary physics processes were included 
in the simulations: decay physics, electromagnetic 
physics and physics of the hadronic (elastic and non-
elastic) interactions. For hadronic processes, the 
Geant4 QGSP_BIC physics list was used [10]. 
Electromagnetic physics was included activating the 
G4EmStandardPhysics_opt4 physics list, able to 
provide high accuracy in the electrons, hadrons and 
ions tracking [11]. 
A total of 1M proton histories have been tracked in 
each simulation run. 
The simulated energy spectra of the primary proton 
beam are reported in Figure 1 at four different depths 
along the SOBP (0.0 mm, 19.0 mm, 25.0 mm, 29.4 mm 
in water). 
 
Figure1. Protons energy spectra at various depths inside the 
water tank 
4.2. Alpha production cross sections 
Proton-Boron total production cross sections are 
needed for the computation of the expected number of 
produced alphas. TALYS-1.9 analytical code [7] was 
used to retrieve them due to its ability to account for all 
different production channels induced by protons 
(Figure 2). 
 
Figure 2. TALYS calculations for the total proton-Boron alpha 
production cross-section (red curve) plotted together with 
cross-section of other possible channels. 
At low energies (below 10 MeV), the 11B(p, α)2α 
channel (green curve of Figure 2) is the only one 
producing alpha particles; experimental cross sections 
for this channel are also available and data can be 
found in the EXFOR database [6]. Figure 3 shows the 
11B(p, α)2α total experimental cross section and the 
corresponding TALYS results when only this channel is 
considered. 
   
 
Figure 3. Experimental and TALYS 11B(p,a)2a total cross 
section vs energy of the incident proton 
Considering that TALYS poorly describes the data 
below 1 MeV, we decided to adopt a combination of the 
two distributions as total cross section: experimental 
data below 4 MeV and TALYS calculations above that 
energy. The final resulting cross section is reported in 
Figure 4. 
 
Figure 4. total alpha production cross section adopted for 
alphas calculation and derived by the combination of 
experimental and TALYS data 
4.3. Alpha estimation 
A quantification of alpha particles generated at any 
depths (Nα) along the SOBP due to the 11B presence 
was performed embedding the simulated proton 
spectra of Figure 1, in the equation: 
 
 (1) 
where σα is the total alpha production cross section 
derived from the union of TALYS and experimental 
data (Figure 4), nx expressed in atoms/m3 (nx = 
3.56·1024 atoms/m3 corresponding to the 11B 
concentration used) and d is the voxel size (100 µm). 
The 11B numerical density nx was estimated using 
the following equation: 
 
 (2) 
where CB is the massic concentration of Boron (80 
ppm in our case), ρtot is the total density of the target 
(in this case it has been taken equal to water) NA is the 
Avogadro constant, MB is the atomic mass of Boron 
and f is the fraction of 11B with respect to the total 
natural Boron amount introduced into the cell culture 
through the BSH agent (here a fraction of 0.8 has been 
considered). 
The final number of alpha particles is calculated by 
scaling the total number of proton Nx in each slide in 
order to obtain a dose of 2 Gy in the middle of the 
SOBP. 
In Figure 5 the estimated number of alphas, at 
different depths in water along the SOBP, is reported 
together with the experimental depth dose 
distribution. 
Fig
ure 5: Number of alphas estimated as a function of depth in 
water inside the phantom (red curve) and the corresponding 
experimental SOBP. Lines connecting points are used as 
guideline. 
5. DISCUSSION 
The average Linear Energy Transfer (or LET) can 
be retrieved considering only the primary proton  
spectra along the SOBP (Figure 1) using the formula: 
 
 (3) 
 
here Li is the ratio between the deposited energy by 
the incident proton with an energy εi and a step length 
li [12]. 
The same definition of Equation 3 can be adopted 
to estimate the LET along the SOBP   also including the 
contribution of the generated alphas nx .  
The calculated LET variation, after the inclusion of 
the generated alphas, appears, on the one hand, to be 
negligible and can be shown that, in order to obtain a 
DMF as the one experimentally observed, a LET of the 
order of 4-30 keV/µm should be observed. On the 
other hand, these LET values can be obtained only with 
a number of alpha particles larger by a factor 102 with 
respect to those reported in Figure 5. In Table 5 the 
proton LET, the total LET (including the generated 
alphas) and the corresponding DMF are reported for 
three different positions along the SOBP, also 
considering an additional alpha particle contribution 
which is a factor 102 larger with respect to the values 
reported in Figure 5. The calculated DMFs values are, 
in this case, closer to the experimental ones. 
   
 
Table 1: DMF estimation (last column) at three different 
depths along the SOBP; Proton dose averaged LET and Total 
dose averaged LET due to the contribution of alpha particles 
are also reported. 
 
6. Conclusion 
Inelastic reactions triggered by energetic protons as 
they slow down across a clinical SOBP  interacting with 
Boron nuclei seem to produce an enhancement of 
proton radiobiological effectiveness. These results, 
even if experimentally well corroborated by repeated 
experimental campaigns [4], seem to fall short of an 
immediate justification by estimations merely based on 
analytical and Monte Carlo evaluations of classical 
dosimetric quantities such as integral dose, LET and 
RBE. 
The total number of alpha particles generated, and 
estimated on the basis of the well-known total 
production cross section of the p-B reaction, does not 
explain the experimental results in terms of an average 
LET increase and, hence, with a corresponding RBE 
enhancement. On the opposite, if classical 
radiobiological models are applied, in order to reach 
the observed DMF values, one would require a  
number of alpha particles larger by a factor 103 with 
respect to the calculated yield. 
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